Ritlecitinib (LITFULO) for Vitiligo: What Patients Need to Know
For years the only FDA-approved topical for vitiligo repigmentation was Opzelura — a cream applied twice daily to affected patches. Ritlecitinib changes the picture in an important way: it is taken as a once-daily oral tablet. That means whole-body coverage from a single pill rather than applying cream to individual patches.
Here is what the research shows, how it compares to Opzelura, and who it is most likely to help.
What ritlecitinib is
Ritlecitinib (brand name LITFULO, made by Pfizer) is an oral JAK3 and TEC family kinase inhibitor. JAK inhibitors work by blocking the signalling pathways that drive the autoimmune attack on melanocytes — the cells that produce skin pigment. By interrupting this pathway, the immune destruction of melanocytes stops, and surviving or follicular melanocytes can begin repigmenting affected patches.
Ritlecitinib is taken as a 50 mg tablet once daily.
It was originally approved by the FDA in June 2023 for alopecia areata — another autoimmune hair loss condition — and subsequently studied specifically for vitiligo in the Phase 3 Tranquillo trial.
How the Phase 3 trial went
The Tranquillo trial enrolled adult and adolescent patients with non-segmental vitiligo. The trial completed enrolment in early 2026, with topline data and regulatory decisions anticipated through 2026.
The outcome data from alopecia areata (where ritlecitinib is already approved) provides context: at the 50 mg dose, meaningful clinical response in hair regrowth was seen in approximately 23% of patients at 24 weeks, with continued improvement at 48 weeks. Vitiligo trial endpoints use different measures — F-VASI75 (75% improvement in facial patch area) and T-VASI50 — but the mechanism is the same.
How it compares to Opzelura
Opzelura (ruxolitinib cream, a JAK1/2 inhibitor) and ritlecitinib are both JAK inhibitors targeting the same underlying immune pathway, but they differ in key ways:
| Ritlecitinib (LITFULO) | Opzelura (ruxolitinib) | |
|---|---|---|
| Form | Oral tablet (once daily) | Topical cream (twice daily) |
| JAK targets | JAK3 / TEC family | JAK1 / JAK2 |
| Coverage | Whole body | Patches you apply to |
| FDA approval for vitiligo | Phase 3 completed 2026 | Approved 2022 |
| Best for | Widespread disease, acral sites, body patches | Facial patches, localised disease |
| Systemic exposure | Yes | Minimal (topical) |
| Boxed warning | Yes (same class warning as other JAK inhibitors) | Yes (at prescription doses) |
The key practical difference is coverage. Opzelura has strong evidence on the face — the clinical trials showed F-VASI75 (75% facial improvement) in around 30% of patients at 52 weeks — but applying cream to large body areas twice daily is impractical and the evidence on trunk and limb patches is weaker than on the face.
An oral tablet treats all areas simultaneously without application limitations. This matters most for patients with widespread disease, extensive body patches, or patches on areas difficult to reach or apply cream consistently.
Who ritlecitinib is most likely to help
Based on the mechanism and the alopecia areata experience, ritlecitinib is most relevant for:
Patients with widespread non-segmental vitiligo — extensive body coverage where topical treatment is impractical. If you have patches across large areas of the torso, back, or limbs, oral treatment is a fundamentally different proposition than cream.
Patients with treatment-resistant acral disease — hands, feet, and fingertips respond poorly to Opzelura alone. Systemic JAK inhibition, combined with NB-UVB, is the most evidence-supported approach for acral sites. A combination of ritlecitinib plus NB-UVB is being studied and likely mirrors the baricitinib + NB-UVB data (44.8% total VASI reduction vs 9.2% placebo in the BARVIT trial).
Patients who cannot use topical treatment consistently — compliance with twice-daily cream application across multiple sites over 12+ months is genuinely challenging. Once-daily oral dosing is simpler.
What the boxed warning means
All JAK inhibitors approved in the US carry a class-level boxed warning covering serious infections, major cardiovascular events, blood clots, cancer, and mortality. This warning was added based on data from tofacitinib (a JAK inhibitor) in a rheumatoid arthritis population — predominantly older patients with existing cardiovascular risk factors.
In younger patients without cardiovascular risk factors, the absolute risk from this warning class is substantially lower. Dermatologists prescribing JAK inhibitors for vitiligo and alopecia areata consider this risk in context. The FDA warning is real and should be discussed with your prescribing physician; it does not make ritlecitinib categorically off-limits, but it does mean it is not appropriate for everyone.
Your dermatologist will typically check your complete blood count, lipid panel, and screen for active infections before starting any oral JAK inhibitor.
What about stopping treatment?
This is one of the most important questions with JAK inhibitors. In the alopecia areata data, patients who stopped ritlecitinib after achieving a response frequently relapsed. The same pattern appears with ruxolitinib (Opzelura) — the LITFULO alopecia areata trial showed meaningful relapse after discontinuation.
This has significant implications for vitiligo: if treatment is stopped after achieving repigmentation, how durable is the response? The Tranquillo vitiligo trial will answer this. In the meantime, the honest position is that JAK inhibitors for vitiligo appear to require either continuous use or a maintenance strategy after the active treatment phase.
This is different from treatments currently in research — anti-IL-15 antibodies like TEV-53408 (Phase 1b) are specifically designed to target the tissue-resident memory T cells responsible for relapse, potentially allowing durable remission after stopping. That research is earlier stage, but it addresses exactly this question.
Current access
Ritlecitinib (LITFULO) is available in the US and several other markets for alopecia areata at 50 mg. Whether it becomes available as a labelled treatment for vitiligo depends on the Tranquillo regulatory outcome. Some patients may be able to access it through off-label prescription — dermatologists in the US are able to prescribe approved medications for off-label uses at their clinical judgement.
If ritlecitinib is approved for vitiligo, access will likely follow a similar path to Opzelura: prior authorisation from insurance, manufacturer patient assistance programmes, and potential appeal processes for initial denials.
The VRF Foundation pipeline page and your dermatologist are the most reliable sources for the latest regulatory status.
How it fits into a treatment plan
Ritlecitinib is not a replacement for Opzelura in all patients — it is an addition to the options available, appropriate for a specific subset. For localised facial vitiligo, Opzelura remains the standard of care with the strongest evidence base. For widespread disease or patients where topical treatment has been inadequate, an oral JAK inhibitor is a meaningful new option.
The combination of an oral JAK inhibitor plus narrowband UVB is likely to become a standard protocol for extensive disease — the mechanism of combining immune suppression (JAK inhibitor) with follicular reservoir stimulation (NB-UVB) is well-supported, and the baricitinib + NB-UVB data gives a clear indication of what that combination can achieve.
Have you or your dermatologist discussed ritlecitinib? I would be interested to hear what the conversation looked like — hit reply to any of my newsletter emails or use the contact page.
Also on VitiligoTreatmentInfo.com
- Opzelura complete patient guide — the most detailed patient-facing review of ruxolitinib cream
- Tacrolimus vs Opzelura: who should use which
- Upadacitinib (Rinvoq) for vitiligo — the other oral JAK inhibitor in the pipeline
- Vitiligo treatment options compared
